Cervical Cancer Diagnostics Market

SKU: DMMD1901 | Last Updated On: Jan 09 2023 | Available Formats

>Cervical Cancer Diagnostics Market Expected to reach a high CAGR of 9.2% By 2030:

Cervical Cancer Diagnostics Market is segmented By Test Type (Pap Smear Test, HPV DNA Test, Coloscopy), By Age Group (Below 21,21-29,30-65,65 and above), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Share, Size, Outlook, and Opportunity Analysis, 2023-2030.


Cervical Cancer Diagnostics Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 9.2% during the forecast period (2023-2030). 

Cervical cancer diagnostics rely on advanced laboratory tests, tools, and processes to assess aberrant human papillomavirus cells or strains (HPV). During colposcopy, a tissue sample obtained through conization, punch biopsy, endocervical curettage, and the electrical wire loop is taken for a complete examination of the cervix. Following identification, blood tests, chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, and visual examinations of the bladder and rectum are performed to establish the disease stage. The global risk of HPV infection is increasing due to the number of people diagnosed with sexually transmitted illnesses (STIs) such as syphilis, chlamydia, gonorrhea, and acquired immune deficiency syndrome (HIV/AIDS).

As per DataM Intelligence, Cervical Cancer Diagnostics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Cervical Cancer Diagnostics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Cervical Cancer Diagnostics Market in the United States and Canada produces the utmost share. Whereas the European Cervical Cancer Diagnostics Market is projected to continue its presence globally during the period of 2022- 2029.

Cervical Cancer Diagnostics Market



Market CAGR


Segments Covered

By Test Type, By Age Group, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into Market, Get Our Sample Brochure

Market Dynamics

The cervical cancer diagnostics market growth is driven by several factors such as the increased prevalence of cervical cancer, proactive initiatives by various government and non-government organizations, awareness among people, technological advancements, and improvement in healthcare infrastructure.

Technological advancements in cervical cancer diagnostics are expected to drive market growth.

There are various technological advancements in the diagnostics of cervical cancer. Many companies are developing new, easier, and faster ways to improve outcomes. For instance, Eve Medical Inc., a company based in Canada, has launched a self-collecting vaginal swab and optional mailer box known as HerSwab that enables the collection of own samples from the vagina/cervix, placing them in a transport bag and mailing it for molecular testing. HerSwab is approved by Health Canada and is for use in European Union. Similarly, an Israeli startup Biop Medical has created an FDA-approved system that is in sterile disposable cover and can be safely inserted in a patient’s cervix where an algorithm directs a high-definition, digital colposcope to the center of the cervix, which emits light and receives its reflection. The light reflected by the cervical tissue indicates the location of any cancerous or pre-cancerous lesions.


In most developing nations, primary healthcare facilities where preventative healthcare such as cervical screening and diagnostic tools should be available are inadequate, under-resourced, and overburdened. Most low-income countries have very inadequate cancer diagnostic services in palliative care. Illiteracy and overpopulation are two key causes of this shortage of primary healthcare. These are the factors the market is expected to get hampered in the forecast period.

Industry Analysis

The cervical cancer diagnostics market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Pap Smear test segment is expected to hold the largest market share in the cervical cancer diagnostics market.

Pap Smear tests accounted for the largest market share in 2021. The segment benefits from its ability to detect cervical cancer at an early stage. A Pap smear test gives a better chance of cure due to early diagnosis. A Pap smear can also detect changes in your cervical cells that suggest cancer may develop in the future. The Pap smear is usually done in conjunction with a pelvic exam. In women older than 30, the Pap test may be combined with a test for human papillomavirus (HPV) — a common sexually transmitted infection that can cause cervical cancer. Therefore, there has been an increase in the adoption of pap smear tests, and the cervical cancer death rate has dropped significantly.

Geographical Analysis

North American region is expected to hold the largest market share in the global cervical cancer diagnostics market.

The North American region accounted for the largest market share in 2021. The region’s growth is attributed to the rise in cases of cervical cancer, an increase in the female population, rising awareness among the population regarding cervical cancer and favorable reimbursement policies. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. In contrast, in 2022, about 14,100 new cases of invasive cervical cancer will be diagnosed, and about 4,280 women will die from cervical cancer. Therefore, the US FDA has approved HPV DNA testing in conjunction with pap smear tests for routine cervical screening of women 30 years and older. There is additional development of screening tests in the US for examining additional markers of HPV infection. The US government provides insurance and reimbursement for cervical screening through Medicaid. It supports efforts to make cervical cancer prevention, screening, and treatment more affordable to help reduce cervical cancer incidence and mortality.

Competitive Landscape

Major key players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Guided Therapeutics, Olympus, Cardinal Health, Siemens Healthcare, Hologic, Inc., Quest Diagnostics, QIAGEN,  OncoHealth Corp., Arbor Vita,  Zilico Ltd.

Abbott Laboratories:


Abbott Laboratories is an American multinational medical device and healthcare company that explores, develops, manufactures, and sells a broad and diversified line of healthcare products. It split off its research-based pharmaceuticals business into AbbVie in 2013. It benefits through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Others. Its well-known products across the medical devices, diagnostics, and nutrition divisions are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. One hundred nine thousand colleagues serve people in more than 160 countries.

Product Portfolio: 

ALINITY m HR HPV ASSAY: The Alinity m High Risk (HR) HPV assay is a qualitative in vitro test for use with the automated Alinity m System for the detection of DNA from 14 high-risk human papillomavirus (HPV) genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 in clinical specimens. The assay specifically identifies HPV genotypes 16, 18, and 45 while reporting the concurrent detection of the other high-risk genotypes (31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68) at clinically relevant infection levels. The Alinity m HR HPV assay is intended for the following uses: To screen patients with ASC-US (atypical squamous cells of undetermined significance) cervical cytology test results to determine the need for referral to colposcopy. The results of this test are not intended to prevent women from proceeding to colposcopy.

  • To be used with cervical cytology to adjunctively screen to assess the presence or absence of high-risk HPV genotype.
  • To be used as a first-line primary screening test to identify women at increased risk for the development of cervical cancer or the presence of high-grade disease.
  • To assess the presence or absence of HPV genotypes 16 and 18 to identify women at increased risk for the development of cervical cancer or the presence of high-grade disease with or without cervical cytology.

The global cervical cancer diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Trending Topics

Breast Cancer Diagnostics Market

Cancer Diagnostic Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!